Mass Tort brief
Corporate Defense Playbooks Face Pivotal Tests
Bayer's clean post-SCOTUS Roundup victory and Meta's settlement contrast with mounting scientific showdowns across GLP-1, Tylenol, and Depo-Provera dockets.
Mass Tort
Meta bought its way out of the courtroom — leaving Snap isolated to defend social media addiction algorithms before a Los Angeles jury.
BackgroundCoordinated California mass tort lawsuits accuse major social platforms of engineering addictive infinite scrolls and push notifications that drive adolescent depression. Google and ByteDance previously reached private settlements, systematically narrowing the defense field before trial.
- Meta settled with plaintiff K.D.B. during final jury selection, avoiding public courtroom scrutiny over internal documents on adolescent mental health.
- Snap Inc. must now defend the bellwether trial alone, with Chief Executive Evan Spiegel expected to testify personally on app design.
- The litigation tests novel product liability theories claiming recommendation algorithms are defective physical products rather than protected first-amendment speech.
Mass Tort
Bayer's clean trial win stripped plaintiffs of their design defect leverage — paving the way for court approval of a $7.25B global settlement.
BackgroundTens of thousands of cancer patients sued Bayer, claiming glyphosate exposure in Roundup herbicide caused non-Hodgkin lymphoma. The Supreme Court recently ruled that federal pesticide labeling laws preempt state failure-to-warn lawsuits, eliminating plaintiffs' strongest legal argument.
- The St. Louis jury rejected remaining design defect and negligence claims, establishing that jurors remain skeptical of cancer links without warning violations.
- The decision marks Bayer's first test under post-SCOTUS ground rules, where plaintiffs were barred from arguing the company hid known cancer risks.
- Federal judges are currently reviewing Bayer's $7.25B class action settlement, which aims to resolve 60,000 remaining active and future Roundup claims.
Mass Tort
Depo-Provera claimants face a November 30 cutoff — forcing thousands of women to submit verified brain scans or risk fighting Pfizer in court alone.
BackgroundDepo-Provera is an injectable progestin contraceptive used by millions of women globally since its initial regulatory clearance. Medical studies published in 2024 uncovered a five-fold spike in meningioma brain tumors among long-term patients, triggering an influx of product liability lawsuits.
- Claimants must submit verified MRI or CT scans demonstrating intracranial meningioma tumors developed after at least one year of consecutive contraceptive usage.
- Patients who miss the November 30 administrative deadline or opt out are transferred to an active federal trial docket without settlement guarantees.
- Compensation tiers depend on severity, paying higher sums to women who underwent invasive surgical craniotomies or suffer permanent cognitive deficits.
Mass Tort
With GLP-1 lawsuits crossing 4,200 claims, federal courts are weighing scientific gatekeeping — a Daubert ruling that could either sink or validate the entire litigation.
BackgroundGLP-1 drugs like Ozempic and Mounjaro stimulate insulin secretion and slow digestion to treat diabetes and obesity. Thousands of patients sued manufacturers Novo Nordisk and Eli Lilly, alleging the treatments induced irreversible stomach paralysis and permanent optic nerve damage.
- The primary gastroparesis multidistrict docket expanded to 4,025 claims, while a separate docket targeting ischemic optic neuropathy vision loss reached 250 suits.
- Federal Judge Karen Marston heard intensive defense arguments challenging whether gastrointestinal testing protocols scientifically prove drug-induced paralysis.
- A favorable defense ruling on the Daubert motions would disqualify plaintiffs' core medical witnesses, potentially gutting thousands of pending federal claims.
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
